We help people with diabetes manage their health more effectively and comfortably through our high quality, affordable biosimilar insulins. We are a leading global biosimilars player in recombinant human insulin and Insulin Glargine and also among a handful of global players working on a novel oral insulin molecule.

We transform the lives of people with cancer through our affordable world-class cancer care therapies. We are at the forefront of finding cures for cancer and have introduced transformational life-saving cancer therapies – both biosimilars and novel biologics – in India. We are now focused on making this high-quality cancer treatment affordable for the global patient population.

We aim to deliver innovative therapies for patients suffering from autoimmune diseases to help them manage these lifelong ailments better. We are working on bringing safe, efficacious, affordable immune-modulator medicines to treat patients coping with these immune-related disorders.

One of India’s largest bio-manufacturing facilities for insulins, monoclonal antibodies and devices

The largest integrated insulin manufacturing and R&D facility in Malaysia

Biocon Biologics develops high quality, affordable biosimilars

One of India’s largest biomanufacturing facilities for insulins, monoclonal antibodies and devices

Set up Asia’s largest integrated Insulin manufacturing and R&D facility in Malaysia

Syngene, India’s first custom research organisation CRO From lead generation to clinical supplies

Internationally reputed CRO and manufacturing organisation

Clientele: Bristol-Myers Squibb, Baxter, Amgen, GSK, Merck KGaA and Herbalife

First listed ‘pure play’ bio-pharmaceuticals company in India

First to launch an ingenuously developed novel biologic in India

First company from India to have a biosimilar commercialised in the U.S and in Japan

Developed and launched Itolizumab – the world’s first novel anti-CD6 monoclonal antibody

One of the largest statins manufacturers in the world, supplying drug substances to over 60 countries

One of the largest producers of immunosuppressant APIs globally

Preferred APIs partner for over 1,000 pharma companies in more than 100 countries

Among the largest biologics manufacturing capacity in India

Set up Asia’s largest integrated insulins manufacturing complex in Malaysia

Among the leading insulins players globally

Among Top 10 Global Biotech Employers as ranked by prestigious US-based Science magazine

Bringing safe, efficacious, affordable immune-modulator medicines to treat immune related disorders and help patients manage their lives better